



PHARMACY UPDATE

December 23, 2019

UPDATE #19-021

Page 1 of 6

This update applies to:

All retail pharmacies

States:

- Oregon
- Washington

Line of business:

- Commercial

**PHARMACY
INQUIRIES ONLY:**

**Claims Processing/
Technical Support**

**Caremark
Claims Processing**

Commercial Pharmacy
Help Desk:
1-800-600-0180

*For optimal service,
this telephone number
is for pharmacy use
only.

MEMBER INQUIRIES:

Refer all member
inquiries to the
appropriate Customer
Service phone number
listed on their Health
Net ID card.

First Quarter 2020 Drug List Changes

The following update includes changes to Commercial drug lists.
Changes apply to all Commercial drug lists unless stated otherwise.

- The Essential Rx Drug List (EDL) is used by Large Groups, Small Groups and Individual Plans.
- The Aon Active Health Exchange Drug List (ADL) is used by groups that purchased plans through the Aon Active Health Exchange.

View the most current version of our drug lists on www.healthnet.com.

QUESTIONS

For questions regarding the information in this update, please contact the Health Net Pharmacy Department at 1-888-802-7001.

The recipient of this fax may make a request to opt out of receiving telemarketing fax transmissions from CVS Caremark in numerous ways: call the toll-free number at 877-265-2711; and/or fax the opt-out request to 401-652-0893, at any time, 24 hours a day, 7 days a week. You also may email an opt-out request to do_not_call@cvscaremark.com. An opt-out request is valid (1) if it identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send fax advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within 30 days of receipt. **An opt-out request will not opt you out of purely informational, non-advertisement, Caremark pharmacy communications such as new implementation notices, formulary changes, point-of sale issues, network enrollment forms, and amendments to the Provider Manual.**

Confidentiality Notice: This fax may contain confidential and protected health information (PHI) intended only for the use of the individual or entity named above. As such it is protected to the fullest extent of the law. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that you received it in error. Any review, dissemination, distribution, or copying of the information in this fax is strictly prohibited. If you received it in error, immediately notify the sender by phone or fax, and our Privacy Office at 888-218-7954, and destroy this fax and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual.

Pharmacy Drug List Changes

First Quarter 2020

Changes listed in the table apply to ADL and EDL unless a specific formulary is noted.

* Tier 1, Tier 2, Tier 3, PV: These preventive medications are covered at \$0 cost share if you have a Preventive Pharmacy benefit.

** Self injectables, when used as chemotherapy adjunct, do not require prior authorization.

AC = Anti-cancer

ADL = AonActive Drug List

EDL = Essential Rx Drug List

NF = Non Formulary

PV = Preventive Benefit

SP = Specialty

Step Therapy = Prior authorization is required if step therapy is not met.

Pharmaceuticals Covered Under the Pharmacy Benefit

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
TIER 1 ADDITIONS AND CHANGES			
TIER 2 ADDITIONS AND CHANGES			
Dovato®	Dolutegravir/lamivudine	Combination HIV integrase inhibitor and synthetic nucleoside analogue Treatment of HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure	
Tresiba®	Insulin degludec	An insulin Treatment of Type 1 diabetes mellitus and Type 2 diabetes mellitus	Tier 2
TIER 3 ADDITIONS AND CHANGES			
Corlanor®	Ivabradine Oral Solution	Hyperpolarization-activated cyclic nucleotide-gated channel blocker Treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate	Tier 3 Step Therapy – must try two beta blockers Added limit of #15 ML per day
Seebri NeoHaler®	Glycopyrrolate Inhalation capsule 15.6 MCG	Anticholinergic/ antimuscarinic agent Treatment of chronic obstructive pulmonary disease	Prior Authorization Required
Vyleesi™	Bremalanotide	A melanocortin receptor agonist	ADL only

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		Treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and NOT due to: A co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance	Prior Authorization Required
Specialty Tier and Other Additions and Changes			
Aemcolo™	Rifamycin sodium	Ansamycin antibacterial Treatment of traveler's diarrhea	Added limit of #12 tablets per fill
Bactroban 2% Cream®	Mupirocin	A topical antibiotic Treatment of impetigo	NF Added limit of #30 grams per fill
Balversa™	Erdafitinib	A fibroblast growth factor receptor (FGFR) kinase inhibitor. Treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has: susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Tier AC Prior Authorization required
Cablivi®	Caplacizumab-yhdp injection	A von Willebrand factor (vWF)-directed antibody fragment Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.	Tier SP (EDL) Tier 3 (ADL) Prior Authorization required
Diacomit®	Stiripentol	An antiepileptic Treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam; there are no clinical data to support the use of Diacomit as monotherapy in Dravet syndrome.	Tier SP (EDL) Tier 3 (ADL) Prior Authorization required
Drizalma Sprinkle™	Duloxetine HCl Cap Delayed Release Sprinkle 20 MG, 30 MG, 40 MG, 60 MG (Base EQ)	A selective serotonin and norepinephrine reuptake inhibitor Treatment of pain associated with diabetic peripheral neuropathy,	NF

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		fibromyalgia and chronic musculoskeletal pain and for the treatment of generalized anxiety disorder and major depressive disorder	
Duaklir Pressair®	Acidinium Br-Formoterol Fum Aero Pow BR Act 400-12 MCG/ACT	Combination long-acting muscarinic antagonist and long-acting beta 2-adrenergic agonist Maintenance treatment of chronic obstructive pulmonary disease (COPD)	NF
Fiasp Penfill®	Insulin Aspart (with Niacinamide) Soln Cartridge 100 Unit/ML	Anti-hyperglycemic Treatment of Type 1 diabetes mellitus and Type 2 diabetes mellitus	NF
Gvoke PFS™	Glucagon	Antihypoglycemic Treatment of severe hypoglycemia in patients with diabetes ages 2 years and above	NF
Mavenclad®	Cladribine	A cytotoxic purine antimetabolite Treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults.	Tier SP (EDL) Tier 3 (ADL) Prior Authorization required
Nayzilam®	Midazolam Nasal	Anti-seizure medication Treatment of intermittent, stereotypic episodes of frequent seizure activity	NF
Nourianz™	Istradefyline Tab 20 MG, 40 MG	An adenosine A2A receptor antagonist Treatment of Parkinson's disease in combination with levodopa/carbidopa	NF
Ozobax™	Baclofen Oral Soln 5 MG/ML	A muscle relaxant and anti-spasmodic Treatment of spasticity resulting from multiple sclerosis.	NF
Rybelsus®	Semaglutide Tab 14 MG, 3 MG, 7 MG	A glucagon-like peptide-1 receptor agonist Treatment of Type 2 diabetes mellitus	NF
Symjepi™	Epinephrine	Sympathomimetic catecholamine Treatment of Type I allergic reactions including anaphylaxis to stinging or biting insects, allergen immunotherapy, food, drugs,	Prior Authorization Required Added limit of #2 per fill

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		diagnostic testing substances, or other allergens	
Tolsura®	Itraconazole	Anti-fungal Treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients: Blastomycosis, pulmonary and extrapulmonary, Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy	Tier SP (EDL) Tier 3 (ADL) Prior Authorization Required
Tosymra™	Sumatriptan Nasal	Serotonin (5-HT) agonist Treatment of acute migraine	NF
Trikafta™	Elexacaftor-Tezacaftor-Ivacaftor	Combined effect of elexacaftor, tezacaftor, and ivacaftor is increased quantity and function of F508del-CFTR at the cell surface, resulting in increased CFTR activity as measured by CFTR mediated chloride transport Treatment of cystic fibrosis in patients with at least one F508del mutation in the CFTR gene	Tier SP (EDL) Tier 3 (ADL) Prior Authorization Required Added limit of #3 tablets per day
Trinaz	Prenatal Vit W/Fe Gluconate=FA	A prenatal multi-vitamin A prescription dietary supplement for use throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years.	NF
Wakix®	Pitolisant HCl Tab 17.8 MG, 4.45 MG 9	A histamine-3 (H3)-receptor antagonist/inverse agonist Treatment of excessive daytime sleepiness (EPS) in adult patients with narcolepsy	NF
Yupelri®	Revefenacin	A long-acting muscarinic antagonist (LAMA) Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)	NF DD=3ML
Zelnorm™	Tegaserod	Serotonin-4 (5-HT4) receptor agonist Treatment of adult women less than 65 years of age with irritable	NF

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		bowel syndrome with constipation (IBS-C)	
Ziextenzo™	pegfilgrastim-bmez	<p>A colony stimulating factor</p> <p>To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia</p>	<p>Tier SP (EDL) Tier 3 (ADL) Prior Authorization Required**</p>